New York State Common Retirement Fund lifted its holdings in shares of Alkermes PLC (NASDAQ:ALKS) by 3.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 449,120 shares of the company’s stock after acquiring an additional 13,126 shares during the period. New York State Common Retirement Fund owned approximately 0.29% of Alkermes worth $22,833,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Toronto Dominion Bank boosted its position in Alkermes by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after buying an additional 212 shares during the last quarter. Greenwood Capital Associates LLC boosted its position in Alkermes by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after buying an additional 41 shares during the last quarter. US Bancorp DE boosted its position in Alkermes by 366.4% in the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock valued at $231,000 after buying an additional 3,122 shares during the last quarter. IFP Advisors Inc boosted its position in Alkermes by 10.9% in the second quarter. IFP Advisors Inc now owns 4,074 shares of the company’s stock valued at $236,000 after buying an additional 402 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in Alkermes in the second quarter valued at approximately $249,000. Institutional investors and hedge funds own 99.69% of the company’s stock.

Alkermes PLC (ALKS) opened at $52.15 on Wednesday. Alkermes PLC has a twelve month low of $46.42 and a twelve month high of $63.40. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. The company had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. Alkermes’s revenue for the quarter was up 20.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.09) earnings per share. equities research analysts anticipate that Alkermes PLC will post -0.59 EPS for the current fiscal year.

A number of equities research analysts recently commented on ALKS shares. ValuEngine upgraded Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Jefferies Group set a $69.00 price target on Alkermes and gave the company a “buy” rating in a report on Friday, August 25th. Citigroup set a $62.00 price target on Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. Credit Suisse Group decreased their price target on Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Finally, Barclays set a $50.00 price target on Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. Alkermes presently has a consensus rating of “Hold” and an average price target of $63.55.

In other news, Director Paul J. Mitchell sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $51.98, for a total transaction of $51,980.00. Following the completion of the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $467,820. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP James M. Frates sold 20,932 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $47.58, for a total value of $995,944.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 109,364 shares of company stock valued at $5,355,310. Corporate insiders own 5.34% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Alkermes PLC (ALKS) Shares Bought by New York State Common Retirement Fund” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/13/alkermes-plc-alks-shares-bought-by-new-york-state-common-retirement-fund.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Stock Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related stocks with our FREE daily email newsletter.